FTRE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
FTRE is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is showing short-term strength, but the broader picture is weak: recent revenue and profitability are declining, analysts have recently cut price targets, and both hedge funds and insiders are selling. With earnings due in a few days and no strong bullish proprietary signal, this is not an attractive long-term entry at the current price.
FTRE is in a short-term bullish setup but not an ideal long-term buy. The MACD histogram is positive and expanding, which supports upside momentum. However, RSI_6 is 75.287, indicating the stock is already extended, and moving averages are converging rather than showing a clean strong uptrend. Price is currently around 11.33-11.50, sitting near resistance at R1 11.333 and below R2 11.9, while pivot support is 10.416. The technical picture suggests near-term momentum, but the stock is not offering a compelling risk/reward entry for a beginner long-term investor.
["Barclays said the sector setup is favorable and TD Cowen upgraded FTRE to Buy in March with a $15 target.", "Options positioning is heavily call-skewed, indicating bullish trader sentiment.", "MACD is positive and expanding, supporting current upside momentum.", "Earnings are scheduled soon, which could create a catalyst if results improve."]
["No recent news in the last week, so there is no fresh positive catalyst from company updates.", "Revenue in Q4 2025 fell 5.24% YoY and net income remained negative, worsening 46.90% YoY.", "EPS declined 48.53% YoY and gross margin also compressed.", "Barclays and Evercore both cut price targets recently, signaling weaker expectations.", "Hedge funds are selling and insider selling has increased sharply.", "RSI is elevated, suggesting the stock is near-term stretched rather than attractive for a fresh entry."]
In 2025/Q4, Fortrea posted weaker results. Revenue fell to 660.5M, down 5.24% year over year. Net income was -32.5M, worsening 46.90% YoY, and EPS declined to -0.35, down 48.53% YoY. Gross margin also slipped to 16.93%, down 1.74% YoY. This shows that the latest quarter season was not improving and the business is still under pressure.
Recent analyst sentiment is mixed but clearly turning more cautious. TD Cowen upgraded FTRE to Buy with a $15 target in March, but more recently Evercore cut its target sharply to $14 from $25 and Barclays lowered its target to $11 from $12 while keeping Equal Weight. Citi and Baird also trimmed targets in late February, and Deutsche Bank maintained Hold with a lower target. Overall, Wall Street still sees some upside potential, but the trend in price targets is negative and the pros-versus-cons view is leaning cautious rather than strongly bullish.
